Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Surface Oncology (Nasdaq: SURF) announced that CEO Rob Ross, M.D., will speak at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:00 am ET. The panel discussion, titled “IOs Wide Open - Opportunity and Challenges in Immuno-Oncology,” is a significant opportunity for the company to discuss advancements in immunotherapy targeting the tumor microenvironment. Interested parties can access a live webcast via the company’s website, with a replay available afterwards.
Surface is focused on developing innovative cancer immunotherapies, including its clinical-stage programs SRF617 and SRF388.
- None.
- None.
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a virtual panel discussion entitled, “IOs Wide Open - Opportunity and Challenges in Immuno-Oncology” at the 2022 Wedbush PacGrow Healthcare Conference. The panel discussion will take place on Tuesday, August 9, 2022, at 8:00 am ET.
A live webcast of the discussion may be accessed by visiting the Investors & Media section of the Surface Oncology website at www.surfaceoncology.com. A replay of the webcast will be available on the company’s website following the presentation.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational, cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
What is Surface Oncology's stock symbol?
When will Rob Ross participate in the Wedbush PacGrow Healthcare Conference?
Where can I watch the Surface Oncology conference panel discussion?
What topics will be discussed at the Surface Oncology panel?
What are Surface Oncology's key clinical-stage programs?
